Screener
Capricor Therapeutics CAPR Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| REVENUE / TOTAL REVENUE | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| OPERATING EXPENSES | ||
| Research and development | 27,376,912 | 18,915,572 |
| General and administrative | 9,395,941 | 6,067,376 |
| TOTAL OPERATING EXPENSES | 36,772,853 | 24,982,948 |
| LOSS FROM OPERATIONS | (36,772,853) | (24,982,948) |
| OTHER INCOME (EXPENSE) | ||
| Other income | 8,145 | 12,485 |
| Investment income | 2,904,506 | 729,542 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's other operating expenses?
- Capricor Therapeutics (CAPR) reported other operating expenses of $36.77M in Q1 2026.
- How has Capricor Therapeutics's other operating expenses changed year-over-year?
- Capricor Therapeutics's other operating expenses increased by 47.2% year-over-year, from $24.98M to $36.77M.
- What is the long-term trend for Capricor Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Capricor Therapeutics's other operating expenses has grown at a 50.3% compound annual growth rate (CAGR), from $21.18M to $108.14M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Capricor Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude